Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

Overview of attention for article published in BMC Medicine, August 2022

Altmetric Badge

Mentioned by

So far, Dimensions has found 4 publications that cite this research output.

Article in Cancer Treatment Reviews (January 2023)

Article in Frontiers in Oncology (January 2023)

Article in Frontiers in Oncology (December 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.